Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124629922 | 12462992 | 2 | F | 201604 | 20160617 | 20160614 | 20160831 | PER | US-JNJFOC-20160505791 | JANSSEN | 13.19 | YR | C | M | Y | 45.36000 | KG | 20160831 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124629922 | 12462992 | 1 | SS | TOPAMAX | TOPIRAMATE | 1 | Oral | Y | U | 15KG783;15KG783;16BG253 +MORE | 0 | 100 | MG | TABLETS | BID | ||||
| 124629922 | 12462992 | 2 | PS | TOPAMAX | TOPIRAMATE | 1 | Oral | Y | U | 15KG783;15KG783;16BG253 +MORE | 20505 | 200 | MG | TABLETS | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124629922 | 12462992 | 1 | Seizure |
| 124629922 | 12462992 | 2 | Seizure |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124629922 | 12462992 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124629922 | 12462992 | Diarrhoea | |
| 124629922 | 12462992 | Fall | |
| 124629922 | 12462992 | Hypersomnia | |
| 124629922 | 12462992 | Product colour issue | |
| 124629922 | 12462992 | Respiratory disorder | |
| 124629922 | 12462992 | Seizure | |
| 124629922 | 12462992 | Syncope | |
| 124629922 | 12462992 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |